TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07247110: A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastati

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,848,688

Rescue Site Savings

+$4,523,904

Unlock Full NCT07247110 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07247110 Rescue Dossier →